Blueprint Medicines Corp (BPMC)

Debra Durso-Bumpus is the Chief People Officer at BPMC since February 2020 and previously served as Senior Vice President, Human Resources from April 2015 to February 2020. " " " She also serves on the board of the Massachusetts Biotechnology Education Foundation. " " "

Philina Lee is the Chief Commercial Officer at BPMC since April 2022, leading the company’s commercial strategy and successful product launches; she previously held roles such as Senior Vice President and Vice President at BPMC. " "

Ariel Hurley has served as Senior Vice President, Finance and Principal Accounting Officer at BPMC since January 2023, and previously held executive finance roles including Vice President, Finance from March 2019 to December 2022. " " "

Becker Hewes, M.D. is the Chief Medical Officer at BPMC since January 2021, and previously served as Senior Vice President of Clinical Development from May 2020 to January 2021. " "

Christina Rossi has served as the COO at BPMC since April 2022, after serving as CCO from October 2018 to April 2022, and holds active board roles at Xilio Therapeutics since April 2021. " "

Christopher K. Murray, Ph.D., has been serving as Chief Technical Operations and Quality Officer at BPMC since January 2023. " " " He previously served as Senior Vice President, Technical Operations from October 2017 to December 2022. " " "

Fouad Namouni is the President, Research and Development at BPMC since September 2020, and he leverages over 20 years of expertise in oncology and cancer immunotherapy drug development. " " Previously, he held several leadership roles at Bristol Myers Squibb from 1999 to 2020. " "

Michael Landsittel has been the Chief Financial Officer of Blueprint Medicines Corporation since January 2019. " He previously served as Vice President, Finance from February 2016 to January 2019 and as Senior Director, Finance from September 2014 to February 2016 at the company. "

Percy H. Carter, M.B.A., Ph.D. has served as the Chief Scientific Officer at BPMC since May 2021. " " He is also an independent board member of HiFiBio Therapeutics since 2022. " "

Tracey L. McCain has served as BPMC's Executive Vice President and Chief Legal Officer since September 2016 and as Chief Compliance Officer since June 2017, bringing extensive legal and compliance expertise from her previous leadership roles at Sanofi Genzyme and Genzyme Corporation. " "

Alexis Borisy has served as a director at BPMC since April 2011. " " " He previously served as the interim CEO from May 2013 through July 2014. " " "

Daniella Beckman has served as an Independent Director at BPMC since 2021 and currently chairs the Audit Committee as the designated Audit Committee Financial Expert. " " " Previously, she served as CFO at Tango Therapeutics starting in 2019 and has held significant financial leadership roles in various biotechnology companies. " "

Habib Dable has served as an Independent Director at BPMC since 2022, contributing to the Compensation and Nominating and Corporate Governance Committees. Previously, he was CEO of Acceleron Pharma from 2016 to 2021 and held various leadership roles at Bayer from 1994 to 2016. " "

Jeffrey W. Albers served as CEO from 2014 until April 3, 2022 and has led BPMC as Chairperson of the Board since June 2021, providing strategic guidance and leadership. " " "

John Tsai, M.D. has served as an independent director at BPMC since January 6, 2023. " " " He brings over 20 years of pharmaceutical industry experience from leadership roles at companies including Novartis, Amgen, and Bristol-Myers Squibb. " " "

Lonnel Coats has been an independent director at Blueprint Medicines Corporation since 2016. " " He also serves as the Chair of the Nominating and Corporate Governance Committee and as a member of the Audit Committee with a designation as an Audit Committee Financial Expert. " " "

Lynn Seely, M.D. has served as an Independent Director at BPMC since 2016 and as Lead Independent Director since June 2021. " " " She also chairs the Compensation Committee and sits on the Nominating and Corporate Governance Committee, while externally serving as President and Chief Executive Officer of Lyell Immunopharma, Inc. since 2022. " "

Mark Goldberg, M.D., has served as an Independent Director at Blueprint Medicines Corporation (BPMC) since 2015. " " " " He is also active in academia and the biopharmaceutical industry, holding roles as a Lecturer in Medicine at Harvard Medical School since 2021 and as a Faculty Member in the Hematology Division at Brigham and Women’s Hospital since 1987. " "

Nicholas Lydon, Ph.D., is the Scientific Founder of BPMC and has been a board member since April 2011. " " He also serves as the chair of the research and development committee at BPMC. "